Canadian marijuana company has been granted permission by the U.S. federal government to export medicinal cannabis to California for scientific research.
The company, Tilray Inc., and Dr. Fatta Nahab, an associate professor of neurosciences at the University of California San Diego’s medical school, who is behind the research, believe it is the first time that the U.S. Drug Enforcement Administration (DEA) has given the green light to a Canadian producer to export a cannabis study drug south of the border, The Toronto Star reported. Getting approval was a months-long process that also required the U.S. Food and Drug Administration (FDA) to agree.
“It’s quite significant,” Dr. Catherine Jacobson, Tilray’s director of clinical research told the Canadian newspaper. “This is the first time a Canadian (licensed producer) has demonstrated to the FDA that a study drug produced in Canada from the cannabis plant can meet its standards.”
Top photo courtesy of Adobe Stock
Latest from Cannabis Business Times
- South Dakota Group Submits 29K Signatures for 2024 Adult-Use Cannabis Legalization Measure
- Rescheduling Would Have Saved Verano $80M in 2023 Tax Payments, CEO Says
- Aurora Marks 1st Medical Cannabis Shipment to New Zealand Market
- Where All 100 US Senators Stand on SAFER Banking Act
- Blumenauer Unveils Legislative Blueprint, Additional Administrative Action Needed Following Rescheduling
- Cannabis Rescheduling FAQ: What Now?
- From Custodian to Cultivation Supervisor
- California City in Cannabis Retail Desert Welcomes 1st Dispensary